Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3
Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3
复制标题
肝脏 IRF2BP2 通过直接抑制 ATF3 的转录来减轻非酒精性脂肪肝。
DOI：
10.1002/hep.30950
复制
发表时间：
2020-01-30
期刊：
影响因子：
13.5
通讯作者：
Wei, Xiang
中科院分区：
文献类型：
--
作者：
Fang, Jing;Ji, Yan-Xiao;Wei, Xiang
虽然近几十年来关于非酒精性脂肪性肝病（NAFLD）发病机制的知识已经有了深刻的发展，但内部限制性机制仍然很大程度上未知。我们最近报道了转录抑制因子干扰素调节因子-2结合蛋白2（IRF 2BP 2）在心肌细胞中富集，并抑制小鼠的病理性心脏肥大。值得注意的是，IRF 2BP 2在肝细胞中大量表达，并在脂肪变性肝脏中显著下调，而IRF 2BP 2在NAFLD中的作用尚不清楚。
Although knowledge regarding the pathogenesis of nonalcoholic fatty liver disease (NAFLD) has profoundly grown in recent decades, the internal restrictive mechanisms remain largely unknown. We have recently reported that the transcription repressor interferon regulatory factor‐2 binding protein 2 (IRF2BP2) is enriched in cardiomyocytes and inhibits pathological cardiac hypertrophy in mice. Notably, IRF2BP2 is abundantly expressed in hepatocytes and dramatically down‐regulated in steatotic livers, whereas the role of IRF2BP2 in NAFLD is unknown.